These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 19746978

  • 1. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
    Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, St Denny I, Taslimi PM, Vash B, Caplan SL.
    J Med Chem; 2009 Oct 08; 52(19):6142-52. PubMed ID: 19746978
    [Abstract] [Full Text] [Related]

  • 2. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
    Haynes NE, Corbett WL, Bizzarro FT, Guertin KR, Hilliard DW, Holland GW, Kester RF, Mahaney PE, Qi L, Spence CL, Tengi J, Dvorozniak MT, Railkar A, Matschinsky FM, Grippo JF, Grimsby J, Sarabu R.
    J Med Chem; 2010 May 13; 53(9):3618-25. PubMed ID: 20405948
    [Abstract] [Full Text] [Related]

  • 3. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M.
    Drug Discov Today; 2009 Aug 13; 14(15-16):784-92. PubMed ID: 19520181
    [Abstract] [Full Text] [Related]

  • 4. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R, Berthel SJ, Kester RF, Tilley JW.
    Expert Opin Ther Pat; 2011 Jan 13; 21(1):13-33. PubMed ID: 21155690
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
    Li F, Zhu Q, Zhang Y, Feng Y, Leng Y, Zhang A.
    Bioorg Med Chem; 2010 Jun 01; 18(11):3875-84. PubMed ID: 20472448
    [Abstract] [Full Text] [Related]

  • 6. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, Berthel SJ, Sarabu R.
    Handb Exp Pharmacol; 2011 Jun 01; (203):357-401. PubMed ID: 21484579
    [Abstract] [Full Text] [Related]

  • 7. Small molecule glucokinase activators as novel anti-diabetic agents.
    Leighton B, Atkinson A, Coghlan MP.
    Biochem Soc Trans; 2005 Apr 01; 33(Pt 2):371-4. PubMed ID: 15787609
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.
    Mol Pharmacol; 2011 Dec 01; 80(6):1156-65. PubMed ID: 21937665
    [Abstract] [Full Text] [Related]

  • 9. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY.
    Bioorg Med Chem; 2014 Apr 01; 22(7):2280-93. PubMed ID: 24588963
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.
    Sarabu R, Grimsby J.
    Curr Opin Drug Discov Devel; 2005 Sep 01; 8(5):631-7. PubMed ID: 16159025
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
    Pfefferkorn JA, Lou J, Minich ML, Filipski KJ, He M, Zhou R, Ahmed S, Benbow J, Perez AG, Tu M, Litchfield J, Sharma R, Metzler K, Bourbonais F, Huang C, Beebe DA, Oates PJ.
    Bioorg Med Chem Lett; 2009 Jun 15; 19(12):3247-52. PubMed ID: 19435665
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
    Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, Grippo JF, Haynes NE, Hutchings S, Garofalo L, Guertin KR, Hilliard DW, Kabat M, Kester RF, Ka W, Liang Z, Mahaney PE, Marcus L, Matschinsky FM, Moore D, Racha J, Radinov R, Ren Y, Qi L, Pignatello M, Spence CL, Steele T, Tengi J, Grimsby J.
    J Med Chem; 2012 Aug 23; 55(16):7021-36. PubMed ID: 22809456
    [Abstract] [Full Text] [Related]

  • 16. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
    Tsumura Y, Tsushima Y, Tamura A, Hasebe M, Kanou M, Kato H, Kobayashi T.
    PLoS One; 2017 Aug 23; 12(2):e0172252. PubMed ID: 28207836
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
    Ishikawa M, Nonoshita K, Ogino Y, Nagae Y, Tsukahara D, Hosaka H, Maruki H, Ohyama S, Yoshimoto R, Sasaki K, Nagata Y, Eiki J, Nishimura T.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4450-4. PubMed ID: 19540111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.